Evidence map›Paper›PMID 40443514›Full record

ArticleFrontiers in medicine2025

Tibetan medicine pain relieving plaster for treatment of knee osteoarthritis: protocol for a multi-center, randomized, and positive drug controlled trial.

Yi Yuan, Ying-Jie Wang, Ai Guo, Wei-Guo Wang, Wei Wang, Pei-Lai Liu, Zhi-Xiu Shen, Jian-Rong Xie, Kai-Lie Liu, Min Zhao and 6 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yi Yuan *Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Ying-Jie Wang *Department of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Ai GuoBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Wei-Guo WangChina-Japan Friendship Hospital, Beijing, China.
Wei WangPeking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Pei-Lai LiuQilu Hospital of Shandong University, Jinan, Shandong, China.
Zhi-Xiu ShenTibet Cheezheng Tibetan Medicine Co., Ltd., Tibet, China.
Jian-Rong XieTibet Cheezheng Tibetan Medicine Co., Ltd., Tibet, China.
Kai-Lie LiuTibet Cheezheng Tibetan Medicine Co., Ltd., Tibet, China.
Min ZhaoTibet Cheezheng Tibetan Medicine Co., Ltd., Tibet, China.
Jing-Ling ZuoCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Kai LiuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Ze-Yang ShiCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Zhao-Lan LiuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Xi-Sheng WengDepartment of Orthopedic Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Jian-Ping LiuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This trial aims to evaluate the effectiveness and safety of a Tibetan medicine pain relieving plaster (PRP) in knee osteoarthritis (KOA) management, generating evidence-based support for clinical application. Method: This multi-center, randomized, positive drug-controlled, non-inferiority trial will evaluate the effectiveness and safety of the PRP in symptomatic participants with KOA. The trial will enroll 440 participants, allocated in a 1:1 ratio to the PRP group and flurbiprofen cataplasms group. All participants will undergo a 7-day treatment period followed by 14-day post-treatment monitoring. We will assess pain severity by the pain dimension score of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, and evaluate knee joint function using the stiffness and joint function dimension scores of the WOMAC scale and knee joint range of motion. We will assess joint swelling by measuring knee circumference. The quality of life will be evaluated using EQ-5D-5L scale, with utility scores calculated based on utility values and changes in the frequency of each level across dimensions. For safety assessment, we will perform blood laboratory tests, detailed recording of adverse events, and assessment of the severity of local skin reactions to the plaster based on a four-point Likert scale. In addition, we will record information related to plaster use, compliance, and the use of rescue therapy. Discussion: This methodologically robust randomized controlled trial will comprehensively characterize PRP's therapeutic potential in KOA management, specifically examining its impacts on core clinical manifestations (pain, mobility restriction, joint swelling) and patient-reported outcomes. The findings will inform evidence-based utilization of this approved Tibetan medicinal formulation in real-world clinical practice.

Indexed as

flurbiprofen cataplasmsknee osteoarthritisnon-inferiority designpain relieving plasterrandomized controlled trialtrial protocol

Identifiers

PMID40443514
PMCPMC12119513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.